Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 58, 2023 - Issue 3
Submit an article Journal homepage
943
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

Rafael A. Leivaa Department of Infectious Diseases, Haukeland University Hospital, Bergen, NorwayCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4750-5861
ORCID Icon,
Bente M. Bergersenb Department of Infectious Diseases, Oslo University Hospital, Ullevål, Norway
,
Ane-Kristine Finbråtenb Department of Infectious Diseases, Oslo University Hospital, Ullevål, Norway;c Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
,
Per Kristian Sandveid Department of Infectious Diseases, Østfold Hospital, Kalnes, Norway
,
Øystein Simonsend Department of Infectious Diseases, Østfold Hospital, Kalnes, Norway
,
Carola M. Rosselande MSD AS, Drammen, Norway
,
Karin Hagenf MSD AB, Stockholm, Sweden
,
Lital Youngg MSD AG, Luzern, Switzerland
,
R. Scott Robertsh LINK Medical AS, Oslo, Norway
,
Yngve Mikkelsenh LINK Medical AS, Oslo, Norway
,
Ravinder Singhe MSD AS, Drammen, Norway
,
Martin Laggingi Department of Infectious Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;j Department of Clinical Microbiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, SwedenORCID Iconhttps://orcid.org/0000-0002-7995-3626
ORCID Icon &
Olav Dalgardk Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway;l Institute for Clinical Medicine, University of Oslo, Oslo, Norway
 show all
Pages 264-268 | Received 30 Apr 2022, Accepted 23 Aug 2022, Published online: 05 Sep 2022

References

  • Bell AM, Wagner JL, Barber KE, et al. Elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis C. Int J Hepatol. 2016;2016:3852126. https://www.hindawi.com/journals/ijh/2016/3852126/
  • Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. A randomized trial C-EDGE treatment naive trial of grazoprevir–elbasvir. Ann Intern Med. 2015;163(1):1–13. https://doi.org/10.7326/M15-0785.
  • Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection – 16 weeks vs 12 weeks. 66th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA 2015. https://www.natap.org/2015/AASLD/AASLD_47.htm
  • Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. https://doi.org/10.1016/j.jhep.2016.09.001.
  • Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.
  • Recommendations on treatment of hepatitis C 2020. J Hepatol. 2020;73(5):1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018.
  • Midgard H. Management of hepatitis C virus infection among people who inject drugs: Treatment uptake, reinfection and risk behaviours [PhD thesis]. University of Oslo; 2017. https://www.duo.uio.no/handle/10852/61510.
  • Ahmed H, Abushouk AI, Menshawy A, et al. Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection. Ann Hepatol. 2018;17(1):18–32. https://www.medigraphic.com/pdfs/hepato/ah-2018/ah181e.pdf
  • Knops E, Sierra S, Kalaghatgi P, et al. Epistatic interactions in NS5A of hepatitis C virus suggest drug resistance mechanisms. Genes (Basel). 2018;9(7):343. https://doi.org/10.3390/genes9070343.
  • Palladino C, Esteban-Cartelle B, Mate-Cano I, et al. Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36(5):262–267. https://doi.org/10.1016/j.eimc.2017.03.008.
  • WHO. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. World Health Organization; 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
  • Wisløff T, White R, Dalgard O, et al. Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies. J Viral Hepat. 2018;25(9):1066–1077. https://doi.org/10.1111/jvh.12904.
  • Toresen KH, Salte IM, Skrede S, et al. Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic. Scand J Gastroenterol. 2014;49(4):465–472. https://doi.org/10.3109/00365521.2013.863965.
  • Sølund C, Hallager S, Pedersen MS, DANHEP group, et al. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scand J Gastroenterol. 2018;53(7):849–856. https://doi.org/10.1080/00365521.2018.1467963.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.